Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
9
×
boston top stories
9
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
9
×
new york blog main
new york top stories
biotech
deals
national
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
gene therapy
hemophilia
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
celgene
crispr
gene editing
pfizer
sangamo therapeutics
startups
vc
alnylam pharmaceuticals
biogen
What
gene
9
×
bio
therapy
roundup
crispr
drug
editing
medicine
race
cas
help
human
long
moves
patients
prices
advanced
alnylam’s
alzheimer’s
approval
aren’t
beam
becker
bff
billions
cancer
cells
close
companies
conference
create
crude
cutting
data
deals
defect
despite
developers
devoted
diagnostic
Language
Current search:
gene
×
" boston top stories "
×
" san francisco top stories "
×
" boston blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
6 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M